These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 34003714)
1. Palifermin as primary mucositis prophylaxis in patients with B-cell Non-Hodgkin lymphoma: a case series. Zembillas AS; Thomas SM; Rotz SJ; Buhtoiarov IN; Hanna R Pediatr Hematol Oncol; 2022 Feb; 39(1):80-82. PubMed ID: 34003714 [No Abstract] [Full Text] [Related]
2. Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning. Coutsouvelis J; Dooley M; Kirkpatrick CM; Avery S; Hopkins R; Spencer A Bone Marrow Transplant; 2022 Aug; 57(8):1329-1331. PubMed ID: 35589999 [No Abstract] [Full Text] [Related]
3. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S; Nickleach D; Gao J; Lonial S; Waller EK Biol Blood Marrow Transplant; 2014 Jun; 20(6):852-857. PubMed ID: 24607557 [TBL] [Abstract][Full Text] [Related]
4. Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan-melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma. Campbell P; Friebe A; Foulstone P; Grigg A; Hempton J; Bajel A Leuk Lymphoma; 2012 Jul; 53(7):1415-6. PubMed ID: 22204452 [No Abstract] [Full Text] [Related]
5. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial. Lucchese A; Matarese G; Manuelli M; Ciuffreda C; Bassani L; Isola G; Cordasco G; Gherlone E Minerva Stomatol; 2016 Feb; 65(1):43-50. PubMed ID: 26862696 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia. Lucchese A; Matarese G; Ghislanzoni LH; Gastaldi G; Manuelli M; Gherlone E Leuk Lymphoma; 2016; 57(4):820-7. PubMed ID: 26428409 [TBL] [Abstract][Full Text] [Related]
7. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases. Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628 [TBL] [Abstract][Full Text] [Related]
8. Generalized white appearance of the oral mucosa. Hyperkeratosis secondary to palifermin. Lerman MA; Treister NS J Am Dent Assoc; 2010 Jul; 141(7):867-9. PubMed ID: 20592407 [No Abstract] [Full Text] [Related]
9. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. Radtke ML; Kolesar JM J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600 [TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study. Lauritano D; Petruzzi M; Di Stasio D; Lucchese A Int J Oral Sci; 2014 Mar; 6(1):27-30. PubMed ID: 24357856 [TBL] [Abstract][Full Text] [Related]
11. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Goldberg JD; Zheng J; Castro-Malaspina H; Jakubowski AA; Heller G; van den Brink MR; Perales MA Bone Marrow Transplant; 2013 Jan; 48(1):99-104. PubMed ID: 22750997 [TBL] [Abstract][Full Text] [Related]
12. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299 [TBL] [Abstract][Full Text] [Related]
18. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368 [TBL] [Abstract][Full Text] [Related]
19. Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience. Keefe D; Lees J; Horvath N Support Care Cancer; 2006 Jun; 14(6):580-2. PubMed ID: 16775651 [TBL] [Abstract][Full Text] [Related]
20. [Effectiveness of palifermin in the prevention of oral mucositis in patients with haematological cancers]. Ayago Flores D; Ferriols Lisart R Farm Hosp; 2010; 34(4):163-9. PubMed ID: 20580585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]